Breaking News

Financial Reports: Covance

By Gil Roth | February 5, 2014

Growth pushed by Late-Stage Development segment

Covance 4Q13

4Q Net Revenues: $623 million (+11%)

4Q Earnings: $36 million (+35%)

FY Net Revenues: $2.4 billion (+10%)

FY Earnings: $179 million (+89%)

Comments: Late-Stage Development revenues grew 15% in 4Q to $395 million, led by 17% growth in central laboratories and 13% growth in clinical development. FY revenues in Late-Stage Development were up 17% to $1.5 billion. Early Development revenues grew 5% in 4Q to $228 million, led by growth in clinical pharmacology and toxicology. For FY, Early Development revenues were flat at $871 million. The company cited discovery support and "certain pharmaceutical chemistry services" as areas of decline during the period.

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016